ShareholdingJul 14, 2026, 11:27 AM
GSK PDMRs & PCAs Acquire Shares via Dividend Reinvestment
AI Summary
GSK plc reported that several Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) acquired ordinary shares and American Depositary Shares (ADS) through dividend reinvestment. These transactions occurred on July 9, 10, and 13, 2026, at prices ranging from £19.5950 to £19.7550 for ordinary shares and $52.4700 for ADS. The acquisitions include both direct share purchases and increases in notional interest in shares held under the company's Deferred Annual Bonus Plan.
Key Highlights
- CEO Luke Miels increased notional interest by 1,241 shares at £19.5950 on July 10, 2026.
- CFO Julie Brown increased notional interest by 1,636 shares at £19.5950 on July 10, 2026.
- President, Corporate Development David Redfern acquired 5,803.725 shares at £19.6297 on July 9, 2026.
- President, Global Supply Chain Regis Simard acquired 2,990.691 shares at £19.6297 on July 9, 2026.
- SVP & Group General Counsel James Ford acquired 1,789.579 shares at £19.6297 on July 9, 2026.
- Chief Digital & Technology Officer Shobie Ramakrishnan increased notional interest by 324 ADS at $52.4700 on July 10, 2026.
- President, Europe Lynn Baxter acquired 20.727 shares at £19.6297 on July 9, 2026.
Price Impact
More from GSK